Mechanisms of resistance in leukemic stem cells
2011-06-10 - English

Immune pathophysiology of ITP
2011-06-10 - English

Clinical management
2011-06-10 - English

First line therapy for myeloma in 2011
2011-06-10 - English

Treatment of MDS
2011-06-10 - English

Vaccination of stem cell transplant recipients
2011-06-10 - English

Late effects
2011-06-10 - English

Pregnancy and thrombosis
2011-06-10 - English

Recurrent venous thrombosis
2011-06-10 - English

1 How to stratify patient risk of recurrent VTE and thereby rationalise duration of anticoagulation
2 Appreciate limited clinical utility of testing for heritable thrombophilia
3 Appreciate work in progress in defining hypercoagulability and the prothrombotic state and how this may potentially influence clinical decision making

Molecular pathogenesis of AML
2011-06-10 - English

Understand Molecular Genetics of AML

Understand How Some Properties of AML Can be mapped to molecular Defects

Understand Therapeutic Implications of Molecular Defects

Unrelated donors
2011-06-10 - English

Cord blood donors
2011-06-10 - English

Haploidentical donors
2011-06-10 - English

New treatments in hemophilia
2011-06-10 - English

Understand novel treatments in hemophilia regarding prophylaxis, inhibitor treatment and gene therapy

Updating treatment of CLL
2011-06-10 - English

Understand the current treatement algorithm for the treatment of CLL
Identify the challenges remaining in the treatment of CLL
Identify the current unmet needs in treatment of CLL

Treatment of CLL in the elderly patients
2011-06-10 - English

Although elderly patients above the age of 70 years represent the largest group of CLL patients, they are heavily underrepresented in clinical trials. A careful assessment of the physical fitness and comorbidity should be performed before initiation of therapy. The burden...(more)

Treatment decisons based on molecular features
2011-06-10 - English

1. Understand the pathobiology of DLBCL
2. Understand driver pathways in DLBCL
3. Understand the relationship of tumor biology to treatment
4. Understand rationale for some treatment approaches.

Role of auto and allografts in Hodgkin lymphoma
2011-06-10 - English

Myelofibrosis
2011-06-10 - English

1) Define assessment of prognosis in Myelofibrosis
2) Discuss role of new therapies vs. conventional therapies in Myelofibrosis
3) Define methods for creating an individualized plan for myelofibrosis patients

Animal models to study red blood cell alloimmunization
2011-06-10 - English

To better understand murine models of RBC alloimmunization

Relevance of RH variants in transfusion of sickle cell patients
2011-06-10 - English

Chair comments
2011-06-10 - English

N/A

Chair comments
2011-06-10 - English
available!

Adherence - are you sure your patients are taking their medicines?
2011-06-11 - English

Understand the different mechanizms that drive patient\'s non adherence to oral TKIs.

Bone marrow stem-cell niche: interplay and regulation
2011-06-11 - English

Clinical and academic perspective
2011-06-11 - English

RITUXIMAB MAINTENANCE SIGNIFICANTLY PROLONGS DURATION OF REMISSION IN ELDERLY PATIENTS WITH MANTLE CELL LYMPHOMA. FIRST RESULTS OF A RANDOMIZED TRIAL OF THE EUROPEAN MCL NETWORK
2011-06-11 - English

DYNAMIC MUTATION PROFILES OF LEUKAEMIC CELL POPULATIONS IN RESPONSE TO TREATMENT ARE REVEALED BY GENOME-WIDE SEQUENCING OF SEQUENTIAL SAMPLES FROM PATIENTS WITH B-CLL
2011-06-11 - English

SILENCING OF RHOA NUCLEOTIDE EXCHANGE FACTOR, ARHGEF3 REVEALS ITS UNEXPECTED ROLE IN IRON UPTAKE
2011-06-11 - English

New antithrombotic agents
2011-06-12 - English

The lecture will help understand the strengths and weaknesses of the new anticoagulants.
The lecture will inform about relative effects of the different treatment alternatives.
Understanding of the practical management of the new agents will be enhanced.